4D Molecular Therapeutics, Inc. (FDMT) Earnings Call Transcripts
4D Molecular Therapeutics, Inc.'s Latest Earnings Call - June 9, 2026
In the second quarter of fiscal year 2026, 4D Molecular Therapeutics, Inc. (FDMT) reported significant advancements in its clinical pipeline, particularly with the 4D-150 program for wet AMD. The company highlighted faster-than-expected enrollment in its Phase III trials, with 4FRONT-1 completing enrollment in under 12 months, surpassing initial projections. Management maintained guidance for upcoming catalysts, including data releases in the first half of 2027, which could drive stock performance as the market anticipates results that may redefine treatment paradigms in retinal diseases.
Reported metrics
| Metric | Value |
|---|---|
| Cash and Cash Equivalents | $458 million (positive) |
| Enrollment in 4FRONT-1 Trial | 500+ patients (positive) |
| Projected Treatment Burden Reduction | 80%+ (positive) |
| Cost of Goods | < $1,000 (neutral) |
| Phase III Data Release Timeline | 1H 2027 (neutral) |
| Projected Start of DME Trial | 2H 2026 (positive) |
Guidance from management
Management maintained guidance for key data releases in 2027, including Phase III results for wet AMD and updates on the DME trial, indicating confidence in their development timeline.
What management said
In terms of catalysts, the big catalysts are next year, kind of first half of next year, there'll be Phase III, 4FRONT-1 data. And second half of next year will be 4FRONT-2 data. This year, we'll have kind of by the middle of the year, we'll have a 2-year duration update for our PRISM trial, kind of our Phase I/II trial in wet AMD and 2-year duration data for our DME Phase II sometime second half of this year. And we...
We certainly do. Yes. We estimate about 40% of patients with wet AMD have bilateral disease. So our development program, we have a planned contralateral eye study that we'll run to provide hopefully a label that supports dosing in the fellow eye.
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape, particularly with emerging TKI therapies and their potential impact on market share. Additionally, there were questions about the pricing strategy and its implications for payer dynamics and patient access.
Main topics on the call
- Faster Enrollment in Phase III Trials — 4DMT reported that the 4FRONT-1 trial for wet AMD completed enrollment with over 500 patients in just under 12 months, compared to an initial estimate of 18 months for 400 patients. Management noted, "the pace and enthus...
- Upcoming Catalysts — Management outlined key upcoming milestones, including 2-year data updates for the PRISM trial and DME Phase II in the second half of 2026, with Phase III data for 4FRONT-1 expected in early 2027. This structured timelin...
- Regulatory Pathway Confidence — Management expressed confidence in their interactions with the FDA, stating that their trial designs are standard and conducive to a productive regulatory path. "Our Phase III trial designs are fairly standard in their d...
- Market Positioning Against Competitors — 4DMT aims to position 4D-150 as a foundational therapy in retinal disease, contrasting with incremental improvements from competitors. Management emphasized, "we're trying to set a whole new treatment paradigm," which co...
Read the full 4D Molecular Therapeutics, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 32 calls on record spanning October 25, 2021 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 32 4D Molecular Therapeutics, Inc. earnings call transcripts on record, spanning October 25, 2021 to June 9, 2026. Based on this history, 4D Molecular Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- FDMT
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 32
- First call
- October 25, 2021
- Most recent
- June 9, 2026
- Reporting cadence
- quarterly